A Study to Evaluate the Safety of DA-3030 and to Explore the Efficacy for Diabetic Neuropathic Pain

NCT01820715 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetic Neuropathy

Interventions

DRUG: 600㎍ of DA-3030 Injection
DRUG: Placebo

Sponsor

Dong-A Pharmaceutical Co., Ltd.